Skip to main content
Top
Published in: Pathology & Oncology Research 4/2011

01-12-2011 | Research

Breast Tumor Characteristics in Hormone Replacement Therapy Users

Authors: Jasmina-Ziva Cerne, Snjezana Frkovic-Grazio, Ksenija Gersak

Published in: Pathology & Oncology Research | Issue 4/2011

Login to get access

Abstract

The aim of this study was to further elucidate the influence of HRT use, regarding duration, regimen and route of administration, on breast tumor characteristics. We evaluated the associations between HRT use and breast tumor characteristics in 530 postmenopausal women diagnosed with invasive breast cancer. Detailed information on HRT use and mammographic attendance were collected through a postal questionnaire. Adjusted odds ratios and 95% confidence intervals were calculated using logistic regression. Tumors in HRT users were significantly smaller, more often of ductal histologic type and with lower grade and lower mitotic index compared to tumors in nonusers. Tumor characteristics did not vary significantly by HRT duration, regimen and route of administration, except for mitotic index, which was more often of score 2 in long-term users, and of score 3 in short-term users. Higher mammographic surveillance among HRT users did not explain our results. We conclude that tumors in HRT users have a more favorable prognostic profile regardless of duration, regimen and route of administration. These effects seem to be due to the influence of HRT on preexisting tumors causing their greater differentiation rather than earlier detection due to mammographic surveillance.
Literature
1.
go back to reference Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef
2.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer, hormone replacement therapy: collaborative reanalysis of data from 51 epidemiology studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047–1059CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer, hormone replacement therapy: collaborative reanalysis of data from 51 epidemiology studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047–1059CrossRef
3.
go back to reference Pines A, Sturdee DW, Birkhauser MH et al (2007) IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10:181–194PubMedCrossRef Pines A, Sturdee DW, Birkhauser MH et al (2007) IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10:181–194PubMedCrossRef
4.
go back to reference Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253PubMedCrossRef Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253PubMedCrossRef
5.
go back to reference Flesch-Janys D, Slanger T, Mutschelknauss E et al (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933–941PubMedCrossRef Flesch-Janys D, Slanger T, Mutschelknauss E et al (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933–941PubMedCrossRef
6.
go back to reference Reeves GK, Beral V, Green J et al (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7:910–918PubMedCrossRef Reeves GK, Beral V, Green J et al (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7:910–918PubMedCrossRef
7.
go back to reference Biglia N, Sgro L, Defabiani E et al (2005) The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31:467–472PubMedCrossRef Biglia N, Sgro L, Defabiani E et al (2005) The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31:467–472PubMedCrossRef
8.
go back to reference Bonnier P, Bessenay F, Sasco AJ et al (1998) Impact of menopausal hormone replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79:278–282PubMedCrossRef Bonnier P, Bessenay F, Sasco AJ et al (1998) Impact of menopausal hormone replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79:278–282PubMedCrossRef
9.
go back to reference Cheek J, Lacy J, Toth-Fejel S et al (2002) The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137:1015–1019PubMedCrossRef Cheek J, Lacy J, Toth-Fejel S et al (2002) The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137:1015–1019PubMedCrossRef
10.
go back to reference Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16:3115–3120PubMed Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16:3115–3120PubMed
11.
go back to reference Chen WY, Hankinson SE, Schnitt SJ et al (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101:1490–1500PubMedCrossRef Chen WY, Hankinson SE, Schnitt SJ et al (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101:1490–1500PubMedCrossRef
12.
go back to reference Stahlberg C, Pedersen A, Andersen Z et al (2004) Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91:644–650PubMed Stahlberg C, Pedersen A, Andersen Z et al (2004) Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91:644–650PubMed
13.
go back to reference Borgquist S, Anagnostaki L, Jirstrom K et al (2007) Breast tumors following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202–2207PubMedCrossRef Borgquist S, Anagnostaki L, Jirstrom K et al (2007) Breast tumors following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202–2207PubMedCrossRef
14.
go back to reference Harding C, Knox WF, Faragher EB et al (1996) Hormone replacement therapy and tumor grade in breast cancer: prospective study in screening unit. BMJ 312:1646–1647PubMed Harding C, Knox WF, Faragher EB et al (1996) Hormone replacement therapy and tumor grade in breast cancer: prospective study in screening unit. BMJ 312:1646–1647PubMed
15.
go back to reference Schuetz F, Diel IJ, Pueschel M et al (2007) Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196:342.e1–342.e9CrossRef Schuetz F, Diel IJ, Pueschel M et al (2007) Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196:342.e1–342.e9CrossRef
16.
go back to reference Delgado RC, Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38:147–156PubMedCrossRef Delgado RC, Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38:147–156PubMedCrossRef
17.
go back to reference Rosenberg LU, Granath F, Dickman PW et al (2008) Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 10:R78PubMedCrossRef Rosenberg LU, Granath F, Dickman PW et al (2008) Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 10:R78PubMedCrossRef
18.
go back to reference Schairer C, Gail M, Byrne C et al (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91:264–270PubMedCrossRef Schairer C, Gail M, Byrne C et al (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91:264–270PubMedCrossRef
19.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
20.
go back to reference Tjonneland A, Christensen J, Thomsen BL et al (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337PubMedCrossRef Tjonneland A, Christensen J, Thomsen BL et al (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337PubMedCrossRef
21.
go back to reference Hwang ES, Chew T, Shiboski S et al (2005) Risk factors for estrogen-positive disease. Arch Surg 140:58–62PubMedCrossRef Hwang ES, Chew T, Shiboski S et al (2005) Risk factors for estrogen-positive disease. Arch Surg 140:58–62PubMedCrossRef
22.
go back to reference Kumar AS, Cureton E, Shim V et al (2006) Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol 14:695–703PubMedCrossRef Kumar AS, Cureton E, Shim V et al (2006) Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol 14:695–703PubMedCrossRef
23.
go back to reference Kavanagh AM, Mitchell H, Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355:270–274PubMedCrossRef Kavanagh AM, Mitchell H, Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355:270–274PubMedCrossRef
24.
go back to reference Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8:29–34PubMedCrossRef Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8:29–34PubMedCrossRef
25.
go back to reference Speroff L (2008) Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 15:393–400PubMedCrossRef Speroff L (2008) Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 15:393–400PubMedCrossRef
Metadata
Title
Breast Tumor Characteristics in Hormone Replacement Therapy Users
Authors
Jasmina-Ziva Cerne
Snjezana Frkovic-Grazio
Ksenija Gersak
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9403-x

Other articles of this Issue 4/2011

Pathology & Oncology Research 4/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine